Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- FUDR (floxuridine)
- ibritumomab
Interactions between your drugs
floxuridine ibritumomab tiuxetan
Applies to: FUDR (floxuridine), ibritumomab
MONITOR: The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow, gastrointestinal tract and heart.
MANAGEMENT: Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.
References (9)
- (2001) "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb
- (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
- (2022) "Product Information. Fluorouracil (fluorouracil)." Roche Laboratories
- (2001) "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn
- (2001) "Product Information. Ellence (epirubicin)." Pharmacia and Upjohn
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Alimta
Alimta is used to treat non-small cell lung cancer and mesothelioma, a form of lung cancer ...
Arranon
Arranon is used to treat T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Clolar
Clolar is a cancer medicine that is used to treat acute lymphoblastic leukemia (a type of blood ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Folotyn
Folotyn is used to treat T-cell lymphoma that has spread throughout the body. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.